Navigation Links
Drug Combo Staves Off Type 2 Diabetes
Date:6/2/2010

Low doses of metformin, Avandia cut risk by two-thirds in study,,

WEDNESDAY, June 2 (HealthDay News) -- In people with pre-diabetes, a low-dose combination of two diabetes drugs -- metformin and Avandia (rosiglitazone) -- appeared to reduce the progression to type 2 diabetes, new research shows.

The study found that the risk of developing type 2 diabetes was reduced by two-thirds in those taking the drug combo compared to those on placebo.

"Diabetes is a complex metabolic disorder, and it's unlikely that there will ever be one magic bullet that treats or prevents diabetes," explained study author Dr. Bernard Zinman, director of the Leadership Sinai Centre for Diabetes at Mount Sinai Hospital and the University of Toronto. "So, more like treatments for HIV/AIDS or cancer that use a drug cocktail, we attempted to look at two drugs that have been known to have beneficial effects in diabetes."

"We were pleasantly surprised to find that using half of the maximum dose was extremely effective for preventing type 2 diabetes," he said.

In addition, Zinman said that the drug combination appeared to counteract the weight gain that's common with Avandia therapy alone. He said that the researchers saw very few side effects in this study.

One major concern about this drug combination, however, is in the use of Avandia. This medication has come under intense FDA scrutiny because it has been associated with an increased risk of heart failure and heart attack. Prescribing information for Avandia now carries a warning that the drug is not recommended for use in anyone with symptomatic heart disease, and that evidence linking the drug with an increased risk of heart attack is still inconclusive.

Zinman said that although this study wasn't designed to assess the safety of Avandia, they didn't see an increase in the risk of cardiovascular disease. He also pointed out that this study used only half the maximum dose of the drug.

Findings from the study, which was funded by Avandia's maker, GlaxoSmithKline, were published in the June 3 online edition of The Lancet.

The trial included 207 adults with impaired glucose tolerance, sometimes called pre-diabetes. Not everyone with impaired glucose tolerance goes on to develop type 2 diabetes, but the condition is associated with long-term cardiovascular risks, according to Dr. Richard Bergenstal, president of medicine and science for the American Diabetes Association.

"Impaired glucose tolerance, although not labeled a disease, is not a benign condition," he said.

The current gold standard of treatment for pre-diabetes, according to Bergenstal, is lifestyle changes such as getting regular exercise and losing weight. And, when maintained, lifestyle changes can be very effective in preventing type 2 diabetes, but such changes aren't always maintained.

"Lifestyle changes have to be the basis for treating diabetes," concurred Zinman, "But, the number of people who implement those changes effectively is small. For someone to lose weight and maintain that weight loss is uncommon."

The study included a year of structured lifestyle intervention for all of the study volunteers. In addition, 103 study participants were given 2 milligrams (mg) of Avandia once a day and 500 mg of metformin twice daily, while 104 people were given placebo pills.

The average follow-up time was 3.9 years, and during that time 14 percent of the drug combo group developed type 2 diabetes, while 39 percent of the placebo group did.

That translates to a 66 percent reduced risk of progressing to diabetes for the treatment group, according to the study.

Additionally, 80 percent of those treated achieved normal blood sugar levels during the study compared to just 53 percent in the placebo group.

"It's critically important that we stem this epidemic of diabetes and we need to start in pre-diabetes. Lifestyle changes can be very effective, and we're gaining more information about which medications or combinations of medications can be helpful in addition to lifestyle changes," said Bergenstal. But, he added, it's not clear from this one small study if this drug combination can truly prevent the progression of pre-diabetes to type 2 diabetes.

More information

To learn more about pre-diabetes and what you can do to prevent type 2 diabetes, visit the American Diabetes Association.



SOURCES: Bernard Zinman, M.D., director, Leadership Sinai Centre for Diabetes, and professor, medicine, Mount Sinai Hospital and the University of Toronto; Richard Bergenstal, M.D., president, medicine and science, American Diabetes Association; June 3, 2010, The Lancet online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Bone Marrow Cancer Patients May Benefit From Drug Combo
2. Short-Term Drug Combo May Help Prevent Colon Cancer
3. Drug Combo Blocks HIV Infection in Mice
4. Combo PET-CT Scans Can Spot Hidden Cancers
5. Blood Thinner Combos Risky for Heart Attack Patients
6. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
7. CSHL scientists discover how a tumor suppressor induces senescence and staves off cancer
8. Nicer than needles: Insulin pills for diabetes finally in clinical trials
9. Just Graduated College Seniors Ride for Loved Ones With Diabetes Cycling Cross Country to Raise Funds to Help Find a Cure
10. Dieting alone may not help stave off type 2 diabetes; muscle mass, strength important
11. TransforMED's Delta-Exchange Teams with Group Practice Forum to Present Free Webinar Series on Diabetes Population Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: